Hiroshi Miyamoto

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. pmc Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Oncol 41:1587-92. 2012
  2. doi request reprint GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:2033-40. 2012
  3. ncbi request reprint Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma
    H Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Curr Cancer Drug Targets 12:14-22. 2012
  4. ncbi request reprint Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Pathol Int 60:1-8. 2010
  5. ncbi request reprint Identification of steroid derivatives that function as potent antiandrogens
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Cancer 117:866-72. 2005
  6. pmc Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells
    Mujib M Rahman
    George Whipple Laboratory for Cancer Research, Department of Biochemistry, and the Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Proc Natl Acad Sci U S A 100:5124-9. 2003
  7. ncbi request reprint Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54
    Zhiming Yang
    George Whipple Lab for Cancer Research, and University of Rochester Medical Center, Rochester, NY 14642, USA
    Endocrinology 148:1340-9. 2007
  8. ncbi request reprint Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth
    Zhiming Yang
    George Whipple Laboratory for Cancer Research, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, New York 14642, USA
    Mol Endocrinol 21:343-58. 2007
  9. pmc 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity
    Hiroshi Miyamoto
    George Whipple Laboratory for Cancer Research, Department of Pathology, and the Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Proc Natl Acad Sci U S A 100:4440-4. 2003
  10. pmc Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation
    Yuanjie Niu
    George Whipple Lab for Cancer Research, Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Cancer Res 68:7110-9. 2008

Collaborators

Detail Information

Publications43

  1. pmc Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Oncol 41:1587-92. 2012
    ..Taken together with our previous findings, crosstalk between EGFR and AR pathways can play an important role in the progression of bladder cancer...
  2. doi request reprint GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:2033-40. 2012
    ..Loss of GATA binding protein 3 was associated with high-grade and/or muscle-invasive tumors, whereas strong expression was an independent predictor of poor prognosis...
  3. ncbi request reprint Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma
    H Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Curr Cancer Drug Targets 12:14-22. 2012
    ..Considerable uncertainty remains regarding the selection of patients who are likely to benefit from hormonal therapy and optimal options for the treatment...
  4. ncbi request reprint Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Pathol Int 60:1-8. 2010
    ..This article outlines the 2004 WHO/ISUP classification system regarding the specific histological criteria for non-invasive papillary urothelial neoplasms and the clinical significance of each category...
  5. ncbi request reprint Identification of steroid derivatives that function as potent antiandrogens
    Hiroshi Miyamoto
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Int J Cancer 117:866-72. 2005
    ..These results strengthen our hypothesis and suggest that selective steroid derivatives could be potent antiandrogenic drugs with less unfavorable effects for the treatment of prostate cancer...
  6. pmc Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells
    Mujib M Rahman
    George Whipple Laboratory for Cancer Research, Department of Biochemistry, and the Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Proc Natl Acad Sci U S A 100:5124-9. 2003
    ....
  7. ncbi request reprint Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with androgen receptor coregulator ARA54
    Zhiming Yang
    George Whipple Lab for Cancer Research, and University of Rochester Medical Center, Rochester, NY 14642, USA
    Endocrinology 148:1340-9. 2007
    ..The novel finding that a protein can modulate AR function without direct interaction with AR might provide a new therapeutic approach to battle prostate cancer by targeting AR indirectly with fewer side effects...
  8. ncbi request reprint Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth
    Zhiming Yang
    George Whipple Laboratory for Cancer Research, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, New York 14642, USA
    Mol Endocrinol 21:343-58. 2007
    ..The finding that a protein can modulate AR function without direct interaction with AR might provide a new therapeutic approach, with fewer side effects, to battle prostate cancer by targeting AR indirectly...
  9. pmc 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity
    Hiroshi Miyamoto
    George Whipple Laboratory for Cancer Research, Department of Pathology, and the Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Proc Natl Acad Sci U S A 100:4440-4. 2003
    ..Further in vivo studies might facilitate the development of a better antiandrogen for the treatment of prostate cancer...
  10. pmc Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation
    Yuanjie Niu
    George Whipple Lab for Cancer Research, Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Cancer Res 68:7110-9. 2008
    ..PSA small interfering RNA or smaller molecules that can degrade PSA protein may be developed as alternative approaches to treat the prostate cancer...
  11. doi request reprint Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:1991-2000. 2012
    ..093) in nuclear semenogelin I positivity as an independent predictor for recurrence. These results suggest that nuclear semenogelin I expression could be a reliable prognosticator in men who undergo radical prostatectomy...
  12. pmc Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling
    Lei Ya Fang
    Authors Affiliations George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York Immunology Research Center, National Health Research Institutes, Zhunan, Miaoli County, and Sex Hormone Research Center, China Medical University and Hospital, Taichung, Taiwan
    Cancer Res 73:5633-46. 2013
    ..Together, our results identify the AR-CCL4-STAT3 axis as key regulators during prostate tumor initiation and highlight the important roles of infiltrating macrophages and inflammatory cytokines for the prostate tumorigenesis...
  13. doi request reprint Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder
    Hiroshi Miyamoto
    Department of Pathology Urology, University of Rochester Medical Center, Rochester, NY, USA
    BJU Int 109:1716-26. 2012
    ..Our data demonstrate that the expression status correlates with tumour grades/stages and patients' outcomes...
  14. ncbi request reprint Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells
    Mujib M Rahman
    George Whipple Laboratory for Cancer Research, Department of Biochemistry, University of Rochester Medical Center, New York 14642, USA
    J Biol Chem 278:19619-26. 2003
    ..ARA70 may, thus, be a critical target for developing therapeutic agents against AR-mediated progression of prostate cancer...
  15. doi request reprint Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York
    Mol Carcinog 53:314-24. 2014
    ..Moreover, UGT1A is likely regulated by estrogens in non-neoplastic urothelium versus bladder tumor in opposite manners, which could be underlying mechanisms of gender-specific differences in bladder cancer incidence and progression...
  16. doi request reprint Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis
    Koji Izumi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Mol Carcinog 52:94-102. 2013
    ..0009)]. These results suggest that androgen-mediated AR signals promote bladder carcinogenesis by down-regulating the expression of UGTs in the bladder...
  17. ncbi request reprint Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications
    Mujib Rahman
    George Whipple Laboratory for Cancer Research, Department of Biochemistry, and the Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    Clin Cancer Res 10:2208-19. 2004
  18. pmc Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor
    Jong Wei Hsu
    George H Whipple Lab for Cancer Research, The Departments of Pathology, Urology, and Radiation Oncology, and The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Am J Pathol 182:1811-20. 2013
    ..Together, these results provide the first direct in vivo evidence that Uro-AR has an important role in promoting bladder tumorigenesis and BCa progression. Targeting AR with ASC-J9 may provide a novel approach to suppress BCa initiation...
  19. pmc Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3
    Spencer Slavin
    Departments of Urology and Pathology, University of Rochester Medical Center Rochester, 601 Elmwood Avenue, NY 14642, USA
    Carcinogenesis 35:1301-9. 2014
    ..Together, these data suggest that CAF ERα could play protective roles in suppressing PCa metastasis. Our results may lead to developing new and alternative therapeutic approaches to battle PCa via controlling ERα signaling in CAF...
  20. pmc Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1
    Aimee M Johnson
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Elmwood Avenue, Rochester, New York, USA
    BMC Urol 8:7. 2008
    ..Furthermore, because BC growth in UPII-SV40T mice is exophytic, we speculated BC growth was dependent on angiogenesis and angiogenesis was, in turn, androgen responsive...
  21. ncbi request reprint Androgen deprivation therapy for prostate cancer: current status and future prospects
    Hiroshi Miyamoto
    George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York, USA
    Prostate 61:332-53. 2004
    ..In order to improve overall survival, novel treatment strategies that prolong the androgen-dependent state and that are useful for androgen-independent disease based on specific molecular mechanisms need to be identified...
  22. doi request reprint Androgen activates β-catenin signaling in bladder cancer cells
    Yi Li
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Endocr Relat Cancer 20:293-304. 2013
    ....
  23. ncbi request reprint Promotion of bladder cancer development and progression by androgen receptor signals
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, 601 Elmwood Ave, Box 626, Rochester, NY 14642, USA
    J Natl Cancer Inst 99:558-68. 2007
    ..Unlike prostate cancer, human bladder cancer is not generally considered to be dependent on hormone activity. We investigated the possible involvement of androgens and the androgen receptor (AR) in bladder cancer...
  24. ncbi request reprint ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor
    Zhiming Yang
    George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    Nat Med 13:348-53. 2007
    ..Collectively, our results point to a better therapeutic and preventative approach to treating SBMA, by disrupting the interaction between AR and AR coregulators...
  25. doi request reprint Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells
    Yichun Zheng
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Endocr Relat Cancer 18:451-64. 2011
    ..Our results indicate that AR activation upregulates the expression of EGFR and ERBB2 in bladder cancer cells. AR signals may thus contribute to the progression of bladder cancer via regulation of the EGFR/ERBB2 pathways...
  26. ncbi request reprint Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, NY 14642, USA
    Nat Clin Pract Oncol 2:236-7. 2005
  27. ncbi request reprint Androgen deprivation therapy for prostate cancer
    Eric A Singer
    Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Expert Opin Pharmacother 9:211-28. 2008
    ....
  28. ncbi request reprint Molecular basis for the antiandrogen withdrawal syndrome
    Hiroshi Miyamoto
    George Whipple Laboratory for Cancer Research, Department of Pathology, and the Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Cell Biochem 91:3-12. 2004
    ....
  29. doi request reprint Expression of semenogelins I and II and its prognostic significance in human prostate cancer
    Anastasia M Canacci
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Prostate 71:1108-14. 2011
    ..Little is known about the role of semenogelins, seminal plasma proteins that play critical roles in semen clotting and subsequent liquefaction in the presence of zinc and prostate-specific antigen, in human malignancies...
  30. ncbi request reprint Role of frozen section analysis of surgical margins during robot-assisted laparoscopic radical prostatectomy: a 2608-case experience
    Yasuhiro Kakiuchi
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 44:1556-62. 2013
    ..Nonetheless, it could be useful in preventing incomplete tumor resection, especially in men with high-grade (Gleason score ≥7) tumor at the apex. ..
  31. doi request reprint Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals
    Yichun Zheng
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA
    Mol Cancer Ther 11:2621-32. 2012
    ..These results may provide a basis of developing improved chemotherapy regimens, including or excluding glucocorticoid receptor agonists/antagonists, for urothelial carcinoma...
  32. doi request reprint The role of the androgen receptor in the development and progression of bladder cancer
    Yi Li
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY 14642, USA
    Jpn J Clin Oncol 42:569-77. 2012
    ....
  33. ncbi request reprint Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer
    Hiroshi Miyamoto
    Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    Mol Carcinog 44:1-10. 2005
    ..We hypothesize that androgen deprivation, in combination with inhibition of the Akt, COX-2, and MMP-9 pathways, delays the androgen-independent transition and has more beneficial effects than hormonal therapy alone...
  34. ncbi request reprint The impact of frozen section analysis during partial nephrectomy on surgical margin status and tumor recurrence: a clinicopathologic study of 433 cases
    Sriram Venigalla
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY
    Clin Genitourin Cancer 11:527-36. 2013
    ..We investigate the utility of intraoperative FSA by evaluating its impact on final surgical margin (SM) status and on patient outcomes...
  35. pmc ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors
    Shinichi Yamashita
    Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Neoplasia 14:74-83. 2012
    ..Successful clinical trials targeting both fAR and AR3 may help us to battle castration-resistant PCa in the future...
  36. doi request reprint Frozen section assessment in testicular and paratesticular lesions suspicious for malignancy: its role in preventing unnecessary orchiectomy
    M Kristina Subik
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Hum Pathol 43:1514-9. 2012
    ....
  37. ncbi request reprint Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression
    Hitoshi Ishiguro
    From the Departments of Pathology and Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, and Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY
    Am J Clin Pathol 142:157-64. 2014
    ..To assess the levels of glucocorticoid receptor (GR) expression in bladder tumors because the status and its prognostic value remain largely unknown...
  38. ncbi request reprint A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth
    Hiroshi Miyamoto
    George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Biol Chem 277:4609-17. 2002
    ..Further studies may provide a new therapeutic approach for blocking AR-mediated prostate cancer growth...
  39. doi request reprint Histopathologic features of atypical glands on prostate biopsy: nucleolar size is a predictor of subsequent detection of prostatic adenocarcinoma
    Sriram Venigalla
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Prostate 73:376-81. 2013
    ....
  40. pmc Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience
    Jennifer Gordetsky
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY Department of Urology, University of Rochester Medical Center, Rochester, New York, USA
    Can Urol Assoc J 5:E47-51. 2011
    ..Very little is known about the role of frozen section analysis (FSA) for these lesions in terms of intraoperative surgical management...
  41. ncbi request reprint Early versus late hormonal therapy for prostate cancer
    Hiroshi Miyamoto
    Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA
    Curr Urol Rep 5:188-96. 2004
    ....
  42. doi request reprint Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion
    Dong Rong Yang
    George H Whipple Laboratory for Cancer Research, Department of Pathology, The Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14646, USA
    Urology 81:1109.e1-6. 2013
    ..To investigate the role of peroxisome proliferator-activated receptor γ (PPARγ) in bladder cancer (BCa) progression...
  43. doi request reprint Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study
    Carmen Mir
    Division of Urology, Mount Sinai Hospital, Rochester, NY, USA
    BJU Int 108:24-30. 2011
    ..To investigate androgen receptor (AR) expression in a large series of patients with bladder cancer (BC) because data on a limited number of patients showed that loss of AR expression was associated with invasive BC...